MNVA news

Latest 1 stories · newest Nov 16, 2026

MNVA
Minerva discusses roluperidone, targeting negative schizophrenia symptoms

Minerva Neurosciences hosted an investor call to discuss the roluperidone program and its potential to treat negative symptoms within schizophrenia. The event featured guest speakers and an update on clinical research.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same MNVA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/MNVA/newsSTART FREE